Mylan’s long-awaited rival for Teva’s blockbuster multiple sclerosis drug Copaxone has been approved in the US, putting a large chunk of the Israeli firm’s revenues at risk. The timing could not have ...

Although only 19% of consumers believe that it's a good time to buy a home, according to a recent survey by Fannie Mae, it's never too early to start building a down payment fund. Money earmarked for ...